Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity

QTc prolongation has been observed during arsenic trioxide and realgar's clinical use, and become a huge obstacle for the application. Our lab has obtained the soluble arsenic from realgar named realgar transforming solution or RTS. In this study, we first evaluated the cytotoxicity on NB4 cell...

Full description

Bibliographic Details
Main Authors: Yang Hai, Peng Song, Xin Wang, Longhe Zhao, Qinjian Xie, Jianyin Li, Yang Li, Hongyu Li
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861319341684
_version_ 1818034555390525440
author Yang Hai
Peng Song
Xin Wang
Longhe Zhao
Qinjian Xie
Jianyin Li
Yang Li
Hongyu Li
author_facet Yang Hai
Peng Song
Xin Wang
Longhe Zhao
Qinjian Xie
Jianyin Li
Yang Li
Hongyu Li
author_sort Yang Hai
collection DOAJ
description QTc prolongation has been observed during arsenic trioxide and realgar's clinical use, and become a huge obstacle for the application. Our lab has obtained the soluble arsenic from realgar named realgar transforming solution or RTS. In this study, we first evaluated the cytotoxicity on NB4 cell and found that RTS could remarkably inhibit proliferation of NB4 than arsenic trioxide. Then we figured out the QTc prolongation of RTS treatment contrasted with arsenic trioxide; results revealed that arsenic trioxide prolonged corrected QTc of mice by 20.1% and showed 1.9-fold higher cytotoxicity on H9c2 cell than RTS. On the contrary, there could not find any QTc prolongation of mice in RTS treatment. Also, arsenic trioxide elevated the intercellular calcium accumulation of H9c2 cell by 2.02-fold v.s control and RTS. HE staining and Masson's trichrome staining had shown that there was no injured section after RTS treatments. IK1 currents of rat ventricular cardiomyocytes were diminished by 45.0% after treating with arsenic trioxide while RTS showed no significance than the control group. The results above indicated that RTS could serve as an alternative arsenic agent on leukemia and had a lower risk of cardiotoxicity. Keywords: Arsenic, Cardiotoxicity, RTS, ATO, Realgar
first_indexed 2024-12-10T06:41:01Z
format Article
id doaj.art-29b611a05acf4d1693ef2fa9c31e6fa8
institution Directory Open Access Journal
issn 1347-8613
language English
last_indexed 2024-12-10T06:41:01Z
publishDate 2019-06-01
publisher Elsevier
record_format Article
series Journal of Pharmacological Sciences
spelling doaj.art-29b611a05acf4d1693ef2fa9c31e6fa82022-12-22T01:58:47ZengElsevierJournal of Pharmacological Sciences1347-86132019-06-011402162170Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicityYang Hai0Peng Song1Xin Wang2Longhe Zhao3Qinjian Xie4Jianyin Li5Yang Li6Hongyu Li7School of Pharmacy, Lanzhou University, Lanzhou, 730020, ChinaInstitute of Microbiology, School of Life Sciences, Lanzhou University, Lanzhou, 730000, ChinaSchool of Pharmacy, Lanzhou University, Lanzhou, 730020, ChinaSchool of Pharmacy, Lanzhou University, Lanzhou, 730020, ChinaGansu Corps Hospital of CAPF, Gansu, 730000, ChinaSchool of Pharmacy, Lanzhou University, Lanzhou, 730020, ChinaSchool of Pharmacy, Lanzhou University, Lanzhou, 730020, ChinaSchool of Pharmacy, Lanzhou University, Lanzhou, 730020, China; Institute of Microbiology, School of Life Sciences, Lanzhou University, Lanzhou, 730000, China; Corresponding author. School of Pharmacy, Lanzhou University, Lanzhou, 730020, China.QTc prolongation has been observed during arsenic trioxide and realgar's clinical use, and become a huge obstacle for the application. Our lab has obtained the soluble arsenic from realgar named realgar transforming solution or RTS. In this study, we first evaluated the cytotoxicity on NB4 cell and found that RTS could remarkably inhibit proliferation of NB4 than arsenic trioxide. Then we figured out the QTc prolongation of RTS treatment contrasted with arsenic trioxide; results revealed that arsenic trioxide prolonged corrected QTc of mice by 20.1% and showed 1.9-fold higher cytotoxicity on H9c2 cell than RTS. On the contrary, there could not find any QTc prolongation of mice in RTS treatment. Also, arsenic trioxide elevated the intercellular calcium accumulation of H9c2 cell by 2.02-fold v.s control and RTS. HE staining and Masson's trichrome staining had shown that there was no injured section after RTS treatments. IK1 currents of rat ventricular cardiomyocytes were diminished by 45.0% after treating with arsenic trioxide while RTS showed no significance than the control group. The results above indicated that RTS could serve as an alternative arsenic agent on leukemia and had a lower risk of cardiotoxicity. Keywords: Arsenic, Cardiotoxicity, RTS, ATO, Realgarhttp://www.sciencedirect.com/science/article/pii/S1347861319341684
spellingShingle Yang Hai
Peng Song
Xin Wang
Longhe Zhao
Qinjian Xie
Jianyin Li
Yang Li
Hongyu Li
Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity
Journal of Pharmacological Sciences
title Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity
title_full Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity
title_fullStr Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity
title_full_unstemmed Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity
title_short Realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity
title_sort realgar transforming solution as a novel arsenic agent with a lower risk of cardiotoxicity
url http://www.sciencedirect.com/science/article/pii/S1347861319341684
work_keys_str_mv AT yanghai realgartransformingsolutionasanovelarsenicagentwithalowerriskofcardiotoxicity
AT pengsong realgartransformingsolutionasanovelarsenicagentwithalowerriskofcardiotoxicity
AT xinwang realgartransformingsolutionasanovelarsenicagentwithalowerriskofcardiotoxicity
AT longhezhao realgartransformingsolutionasanovelarsenicagentwithalowerriskofcardiotoxicity
AT qinjianxie realgartransformingsolutionasanovelarsenicagentwithalowerriskofcardiotoxicity
AT jianyinli realgartransformingsolutionasanovelarsenicagentwithalowerriskofcardiotoxicity
AT yangli realgartransformingsolutionasanovelarsenicagentwithalowerriskofcardiotoxicity
AT hongyuli realgartransformingsolutionasanovelarsenicagentwithalowerriskofcardiotoxicity